Medication adherence and the use of long-acting antipsychotics in bipolar disorder

Journal of Psychiatric Practice

Volumn 13, Issue 2, 2007, Pages 79-85

  El Mallakh, Rif S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Antipsychotic medications; Bipolar disorder; Depot antipsychotics; Intramuscular antipsychotics; Long term treatment; Relapse prevention; Risperidone

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; LORAZEPAM; MICROSPHERE; NEUROLEPTIC AGENT; OLANZAPINE; POLYGLACTIN; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGITATION; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG PACKAGING; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MEDLINE; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RATING SCALE; REVIEW; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CONTROLLED CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; PATIENT COMPLIANCE; RECURRENCE; TREATMENT OUTCOME;

EID: 34247135842     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000265764.87376.02     Document Type: Review

References (78)

1. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.
2. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24.
3. Coryell W, Endicott J, Maser JD, et al. The likelihood of recurrence in bipolar affective disorder: The importance of episode recency. J Affect Disord 1995;33:201-6.
4. Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997;95:361-3.
5. Colom F, Vieta E. Treatment adherence in bipolar patients. Clin Approaches Bipolar Disord 2002;1:49-56.
6. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
7. Scott J. Predicting medication non-adherence in severe affective disorders. Acta Neuropsychiatrica 2000;12:128-30.
8. Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high risk patient group on and off lithium long-term treatment. J Affect Disord 1992;25:261-9.
9. Greenhouse WJ, Meyer B, Johnson SL. Coping and medication adherence in bipolar disorder. J Affect Disord 2000;59:237-41.
10. Scott J. Using health belief models to understand the efficacy-effectiveness gap for mood stabilizer treatments. Neuropsychobiol 2002;46(suppl 1):13-5.
11. Keck PE Jr., McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-52.
12. Weiss RC, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998; 59:172-4.
13. Maarbjerg K, Aagaard J, Vestegaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry 1988;21:121-5.
14. Frank E, Prien RF, Kupfer DJ, et al. Implications of noncompliance on research in affective disorders. Psychopharmacol Bull 1985;21:37-42.
15. Schumann C, Lenz G, Berghofer A, et al. Non-adherence with long-term prophylaxis: A 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 1999;89:247-57.
16. Sajatovic M, Bauer MS, Kilbourne AM, et al. Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv 2006;57:56-62.
17. Urquhart J. Role of patient compliance in clinical pharmacokinetics: A review of recent research. Clin Pharmacokinet 1994;27:202-15.
18. Colom F, Vieta E, Martinez-Aran A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-55.
19. Svarstad BL, Shireman RL, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11.
20. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalizations. Am J Psychiatry 2002;159:1927-9.
21. Dogan S, Sabanciogullari S. The effects of patient education in lithium therapy on quality of life and compliance. Arch Psychiatr Nurs 2003;17:270-5.
22. Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: Beyond compliance enhancement. J Clin Psychiatry 2003;64:1101-5.
23. Rohland BM, Rohrer JE, Richards CC. The long-term effect of outpatient commitment on service use. Admin Policy Mental Health 2000;27:383-94.
24. Tohen M, Zhang F, Taylor CC, et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001;65:85-93.
25. Keck PE Jr., McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment in patients with bipolar disorder. J Clin Psychiatry 1996;57:147-51.
26. Verdoux H, Gonzales B, Takei N, et al. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996;38:81-7.
27. Ozerdem A, Tunca Z, Kaya N. The relatively good prognosis of bipolar disorders in a Turkish bipolar clinic. J Affect Disord 2001;64:27-34.
28. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26.
29. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.
30. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-9.
31. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9.
32. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-7.
33. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-7.
34. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-55.
35. Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: A randomized, double-blind trial. J Clin Psychiatry 2006;67:1747-53.
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
37. Tohen M, Vieta E, Ketter T, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88 (Erratum Arch Gen Psychiatry 2004;61:176).
38. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-90.
39. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.
40. Tohen MF, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute manic and maintenance of remission: A 47-week study. Am J Psychiatry 2003;160:1263-71.
41. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-46.
42. Keck PE Jr., Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
43. Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2006 Dec 15 (e-pub ahead of print)
44. McElroy SL, Suppes T, Frye MA, et al. Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. J Affect Disord 2007 Jan 15; [Epub ahead of print]
45. Tran-Johnson TK, Sack DA, Marcus RN et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:111-9.
46. Andrezina R, Joseassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281-92.
47. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: Double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005;187:235-42.
48. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37
49. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-21.
50. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-23.
51. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-9. Erratum in: J Clin Psychopharmacol 2007;27:51.
52. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A doubleblind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-9.
53. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-54.
54. Keck PE Jr., Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-8.
55. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-16.
56. Rendell JM, Geddes JR. Risperidone in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2006 Oct 18;(4):CD004999.
57. Johnson G, Gershon S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of manic states. Br J Psychiatry 1971;126:267-76.
58. Prien RF, Caffey EM Jr., Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26:146-53.
59. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania: A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32:34-42.
60. Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 1975;32:1310-8.
61. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007;27:35-45.
62. Elliott KJ, Lewis S, El-Mallakh RS, et al. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia. Ann Clin Psychiatry 1994;6:197-203.
63. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68(suppl 1):20-7.
64. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148: 723-5.
65. Gruber AJ, Cole JO. Antidepressant effects of flupenthixol. Pharmacotherapy 1991;11:450-9.
66. Poldinger W, Sieberns S. Depression-inducing and antidepressive effects of neuroleptics. Experiences with flupenthixol and flupenthixol decanote. Neuropsychobiol 1983;10:131-6.
67. Naylor GJ, Scott CR. Depot injections for affective disorders. Br J Psychiatry 1980;136:105-8.
68. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64:226-37.
69. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-22.
70. Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986;1(suppl 1):53-62.
71. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165:827-9.
72. Fernando J, Krishna Raju R, Jones GG, et al. The use of depot neuroleptic haloperidol decanoate. Acta Psychiatr Scand 1984;69:175-6.
73. Fiolet J. Experience with depot neuroleptics in ambulatory practice. Acta Psychiatr Belgica 1981;81:182-8.
74. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
75. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9.
76. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
77. Lindenmayer JP, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44.
78. Masand PS, Wang X, Gupta S, et al. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. Primary Care Companion J Clin Psychiatry 2002;4:70-3.